New biosimilar launches in the UK, campaigners say Donald Trump’s Brexit trade plan will damage the NHS, and fake medications are “easily” bought on Facebook. These are some of the top stories making headlines across pharma this week!
Interested in Star’s innovative outsourcing and resourcing solutions?
Contact Head of Business Development, Ryan Wooller, at firstname.lastname@example.org, or get in touch on 07748 464 079.
On the hunt for a new role, or just curious?
Visit our candidate page, submit your CV to email@example.com, or give our offices a ring!
In the midst of the US administration’s objectives for a post-Brexit trade deal with the UK is a section calling for “procedural fairness” for pharmaceuticals, which is raising hackles in some quarters.
Biogen has agreed to buy UK-based gene therapy biotech Nightstar, which focuses on using modified viruses as therapies for inherited retinal disorders, in a deal worth $800 million.
Napp Pharmaceuticals has launched Pelmeg in the UK, marking the group's first launch of a product developed by Cinfa Biotech, acquired by the Mundipharma network of independent associated companies in October last year.
Counterfeit Xanax that contains a drug called etizolam and is responsible for an epidemic of deaths in Scotland can be bought quickly and easily through sites like Facebook, according to BBC report.
While you’re here…
…and are interested in our content, why not sign up to our newsletter? It’s just below here.